Eli Lilly and Company (LLY) — Stock Price, Financials & Analysis

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Key Statistics — LLY

  • Latest Close: $1215.02
  • Market Cap: $1.08T
  • P/E Ratio (TTM): 40.8
  • EPS (TTM): $29.81
  • Dividend Yield: 56.00%
  • Beta: 0.51
  • 52-Week High: $1249.45
  • 52-Week Low: $629.40
  • Profit Margin: 33.5%
  • Return on Equity: 102.3%
  • Debt to Equity: 162.1

Sector: Healthcare — Drug Manufacturers - General

Income Statement — LLY

  • 2021: Revenue N/A, Net Income N/A
  • 2022: Revenue $28.54B, Net Income $6.24B
  • 2023: Revenue $34.12B, Net Income $5.24B
  • 2024: Revenue $45.04B, Net Income $10.59B
“”Wednesday, August 12, 2026
Minimaxmax⁡x∈Δmin⁡y∈Δ x⊤ ⁣A y=v∗\max_{x \in \Delta} \min_{y \in \Delta} \, x^\top\! A \, y = v^*maxx∈Δ​miny∈Δ​x⊤Ay=v∗§Zero-Sum∑i=1nui(s)=0    ∀ s∈S\textstyle\sum_{i=1}^{n} u_i(s) = 0 \;\; \forall \, s \in S∑i=1n​ui​(s)=0∀s∈S§Nash Eq.x∗⊤ ⁣Ay≥x∗⊤ ⁣Ay∗≥x⊤ ⁣Ay∗x^{*\top}\! A y \geq x^{*\top}\! A y^* \geq x^\top\! A y^*x∗⊤Ay≥x∗⊤Ay∗≥x⊤Ay∗§ExpectedE[u1]=x⊤ ⁣A y\mathbb{E}[u_1] = x^\top\! A \, yE[u1​]=x⊤Ay§RegretRT=max⁡i∑t=1Tuit−∑t=1TuattR_T = \max_i \sum_{t=1}^{T} u_i^t - \sum_{t=1}^{T} u_{a_t}^tRT​=maxi​∑t=1T​uit​−∑t=1T​uat​t​§LP Dualmin⁡y,ww    s.t.    Ay≤w⋅1\min_{y,w} w \;\; \text{s.t.} \;\; Ay \leq w \cdot \mathbf{1}miny,w​ws.t.Ay≤w⋅1§Payoffu1(i,j)=aij,    u2(i,j)=−aiju_1(i,j) = a_{ij}, \;\; u_2(i,j) = -a_{ij}u1​(i,j)=aij​,u2​(i,j)=−aij​§Minimaxmax⁡x∈Δmin⁡y∈Δ x⊤ ⁣A y=v∗\max_{x \in \Delta} \min_{y \in \Delta} \, x^\top\! A \, y = v^*maxx∈Δ​miny∈Δ​x⊤Ay=v∗§Zero-Sum∑i=1nui(s)=0    ∀ s∈S\textstyle\sum_{i=1}^{n} u_i(s) = 0 \;\; \forall \, s \in S∑i=1n​ui​(s)=0∀s∈S§Nash Eq.x∗⊤ ⁣Ay≥x∗⊤ ⁣Ay∗≥x⊤ ⁣Ay∗x^{*\top}\! A y \geq x^{*\top}\! A y^* \geq x^\top\! A y^*x∗⊤Ay≥x∗⊤Ay∗≥x⊤Ay∗§ExpectedE[u1]=x⊤ ⁣A y\mathbb{E}[u_1] = x^\top\! A \, yE[u1​]=x⊤Ay
0∑×$0 sometimesAlpha v0.1.0

The Shounya

HomeScreenerHeatmapSectorsDividendsCompareWatchlistPortfolioChartTechnicalScannerEarningsCorrelationSector AnalysisInsidersCongressNewsLearnAboutStatus
← Home← ScreenerChart TerminalTechnical
LLYHealthcare

Eli Lilly and Company — Healthcare · Drug Manufacturers - General

$1215.02-16.92 (-1.37%)
Mkt Cap
$1.08T
P/E
40.8
EPS
$29.81
Beta
0.51
Yield
56.00%
52W Hi
$1249.45
52W Lo
$629.40
Vol
3.0M

Price History

Chart Terminal →Technical Analysis →

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
50,000
HQ
Indianapolis, IN, United States
Web
lilly.com

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Top Executives

NameTitleTotal Pay
Mr. Lucas E. MontarceExecutive VP & CFO$3.2M
Ms. Anat Hakim J.D.Executive VP, General Counsel & Secretary$3.3M
Mr. Jacob S. Van NaardenExecutive VP, President of Lilly Oncology & Head of Corporate Business Development$3.0M
Mr. Donald A. ZakrowskiSenior VP of Finance & Chief Accounting Officer—
Mr. Diogo RauExecutive VP and Chief Information & Digital Officer$1.1M
Mr. Eric DozierExecutive VP & Chief People Officer—
Mr. Ilya YuffaExecutive VP and President of Lilly USA & Global Customer Capabilities—
Mr. Patrik JonssonExecutive VP & President of Lilly International$1.7M
Mr. Frank CunninghamSenior Vice President of Global Value & Access—
Mr. Edgardo HernandezExecutive VP & President of Manufacturing Operations—

Financial Statements

✓
Profitable
4/5 periods
✓
Revenue Growing
+44.7% latest, 3/3 up
✓
Earnings Growing
+94.9% latest, 2/3 up
✗
Pays Dividend
No dividends
✓
Positive Margin
33.5% net margin

Eli Lilly and Company

Healthcare \u00b7 Drug Manufacturers - General

Market Cap$1.08T
Trailing P/E40.8
Forward P/E26.1
EPS (trailing)$29.81
EPS (forward)$46.56
Gross Margin83.4%
Operating Margin54.2%
Profit Margin33.5%
Dividend Rate$6.92/share
Dividend Yield56.0%
Payout Ratio21.7%

Revenue & Net Income

2021 – 2025, Annual

Revenue

Net Income

Profit Margins

2021 – 2025, Annual

Earnings Per Share

2021 – 2025, Annual

Dividends

No dividend history available.

Price Ranges

52-Week
$629.40$1249.45
Fwd P/E26.1
Avg Volume3.0M
Shares Out0.89B

Key Ratios

Gross Margin83.4%
Operating Margin54.2%
Profit Margin33.5%
ROE102.3%
ROA20.4%
P/B34.8
D/E162.07
Current Ratio1.35
Dividend Rate$6.92
Payout Ratio21.7%

Cash & Debt

Cash 14%Debt 86%
Total Cash$8.95B
Total Debt$54.91B
Net Cash$-45.96B
Free Cash Flow$11.07B
Operating CF$28.08B

Ratings Snapshot

2.7 / 5
P/E1/5(40.8)
P/B1/5(34.8)
ROE5/5(102.3)
ROA5/5(20.4)
D/E1/5(162.1)
Liquidity3/5(1.4)

Growth Pulse

Revenue Growth+47.7%
Earnings Growth+26.2%

Analyst Recommendations

0m
Buy (28 analysts)
5
17
4
Strong Buy: 5
Buy: 17
Hold: 4
Sell: 1
Strong Sell: 1
MonthStr BuyBuyHoldSellStr Sell
0m517411
-1m517411
-2m617511
-3m618511

Income Snapshot 2025

Revenue
$65.2B
Net Income
$20.6B
Gross Margin
83.0%
Net Margin
31.7%
Op. Income
$29.7B
EPS
$23.00

Balance Sheet

2021 – 2025, Annual
Debt / Equity1.60x
Moderate leverage
Current Ratio1.58x
Can easily cover short-term bills
Net Debt$35.23B
Total debt minus cash on hand

Assets vs Liabilities vs Equity

Assets = Liabilities + Equity. The green bar is what's left for shareholders after paying all debts.

Cash vs Debt

How much cash the company has on hand vs how much it owes in total debt.

Period Detail

PeriodAssetsLiabilitiesEquityCashDebtD/E
2021N/AN/AN/AN/AN/A—
2022$49.49B$38.71B$10.65B$2.07B$16.24B1.52x
2023$64.01B$53.14B$10.77B$2.82B$25.23B2.34x
2024$78.72B$64.44B$14.27B$3.27B$33.64B2.36x
2025$112.48B$85.94B$26.54B$7.27B$42.50B1.60x

Balance Sheet Snapshot 2025

Total Assets$112.48B
Total Liabilities$85.94B
Equity$26.54B
Retained Earnings$24.47B
Goodwill$5.90B
Long-Term Debt$40.87B

Cash Flow Statement

2021 – 2025, Annual

Operating · Investing · Financing

Operating — cash from core business.Investing — buying/selling long-term assets.Financing — debt, equity & dividends.

Free Cash Flow

Operating cash flow minus capital expenditure — the cash available after maintaining operations.

PeriodOperatingInvestingFinancingFCFCapEx
2021$0$0$0$0$0
2022$8B$-4B$-5B$5B$-3B
2023$4B$-7B$3B$-3B$-7B
2024$9B$-9B$1B$414M$-8B
2025$17B$-11B$-2B$6B$-11B

Capital Allocation 2025

CapEx$10.85B
Dividends Paid$5.38B
Buybacks$4.11B
Debt Repaid$778.0M
Debt Issued$13.17B
Net Change Cash$3.63B

Price History

Chart Terminal →Technical Analysis →

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
50,000
HQ
Indianapolis, IN, United States
Web
lilly.com

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Top Executives

NameTitleTotal Pay
Mr. Lucas E. MontarceExecutive VP & CFO$3.2M
Ms. Anat Hakim J.D.Executive VP, General Counsel & Secretary$3.3M
Mr. Jacob S. Van NaardenExecutive VP, President of Lilly Oncology & Head of Corporate Business Development$3.0M
Mr. Donald A. ZakrowskiSenior VP of Finance & Chief Accounting Officer—
Mr. Diogo RauExecutive VP and Chief Information & Digital Officer$1.1M
Mr. Eric DozierExecutive VP & Chief People Officer—
Mr. Ilya YuffaExecutive VP and President of Lilly USA & Global Customer Capabilities—
Mr. Patrik JonssonExecutive VP & President of Lilly International$1.7M
Mr. Frank CunninghamSenior Vice President of Global Value & Access—
Mr. Edgardo HernandezExecutive VP & President of Manufacturing Operations—

Price Ranges

52-Week
$629.40$1249.45
Fwd P/E26.1
Avg Volume3.0M
Shares Out0.89B

Key Ratios

Gross Margin83.4%
Operating Margin54.2%
Profit Margin33.5%
ROE102.3%
ROA20.4%
P/B34.8
D/E162.07
Current Ratio1.35
Dividend Rate$6.92
Payout Ratio21.7%

Cash & Debt

Cash 14%Debt 86%
Total Cash$8.95B
Total Debt$54.91B
Net Cash$-45.96B
Free Cash Flow$11.07B
Operating CF$28.08B

Ratings Snapshot

2.7 / 5
P/E1/5(40.8)
P/B1/5(34.8)
ROE5/5(102.3)
ROA5/5(20.4)
D/E1/5(162.1)
Liquidity3/5(1.4)

Growth Pulse

Revenue Growth+47.7%
Earnings Growth+26.2%

Analyst Recommendations

0m
Buy (28 analysts)
5
17
4
Strong Buy: 5
Buy: 17
Hold: 4
Sell: 1
Strong Sell: 1
MonthStr BuyBuyHoldSellStr Sell
0m517411
-1m517411
-2m617511
-3m618511

Financial Statements

✓
Profitable
4/5 periods
✓
Revenue Growing
+44.7% latest, 3/3 up
✓
Earnings Growing
+94.9% latest, 2/3 up
✗
Pays Dividend
No dividends
✓
Positive Margin
33.5% net margin

Eli Lilly and Company

Healthcare \u00b7 Drug Manufacturers - General

Market Cap$1.08T
Trailing P/E40.8
Forward P/E26.1
EPS (trailing)$29.81
EPS (forward)$46.56
Gross Margin83.4%
Operating Margin54.2%
Profit Margin33.5%
Dividend Rate$6.92/share
Dividend Yield56.0%
Payout Ratio21.7%

Revenue & Net Income

2021 – 2025, Annual

Revenue

Net Income

Profit Margins

2021 – 2025, Annual

Earnings Per Share

2021 – 2025, Annual

Dividends

No dividend history available.

Income Snapshot 2025

Revenue
$65.2B
Net Income
$20.6B
Gross Margin
83.0%
Net Margin
31.7%
Op. Income
$29.7B
EPS
$23.00

Balance Sheet

2021 – 2025, Annual
Debt / Equity1.60x
Moderate leverage
Current Ratio1.58x
Can easily cover short-term bills
Net Debt$35.23B
Total debt minus cash on hand

Assets vs Liabilities vs Equity

Assets = Liabilities + Equity. The green bar is what's left for shareholders after paying all debts.

Cash vs Debt

How much cash the company has on hand vs how much it owes in total debt.

Period Detail

PeriodAssetsLiabilitiesEquityCashDebtD/E
2021N/AN/AN/AN/AN/A—
2022$49.49B$38.71B$10.65B$2.07B$16.24B1.52x
2023$64.01B$53.14B$10.77B$2.82B$25.23B2.34x
2024$78.72B$64.44B$14.27B$3.27B$33.64B2.36x
2025$112.48B$85.94B$26.54B$7.27B$42.50B1.60x

Balance Sheet Snapshot 2025

Total Assets$112.48B
Total Liabilities$85.94B
Equity$26.54B
Retained Earnings$24.47B
Goodwill$5.90B
Long-Term Debt$40.87B

Cash Flow Statement

2021 – 2025, Annual

Operating · Investing · Financing

Operating — cash from core business.Investing — buying/selling long-term assets.Financing — debt, equity & dividends.

Free Cash Flow

Operating cash flow minus capital expenditure — the cash available after maintaining operations.

PeriodOperatingInvestingFinancingFCFCapEx
2021$0$0$0$0$0
2022$8B$-4B$-5B$5B$-3B
2023$4B$-7B$3B$-3B$-7B
2024$9B$-9B$1B$414M$-8B
2025$17B$-11B$-2B$6B$-11B

Capital Allocation 2025

CapEx$10.85B
Dividends Paid$5.38B
Buybacks$4.11B
Debt Repaid$778.0M
Debt Issued$13.17B
Net Change Cash$3.63B
0∑×

Free market data & analysis tools.

Markets
HomeScreenerHeatmapSectorsEarnings
Tools
WatchlistCompareChart TerminalTechnical
Research
CongressInsidersDividendsCorrelation
© 2026 ShounyaAlpha v0.1.0Not financial advice · hanabira.org